-
Lemzoparlimab: Targeting CD47 for Cancer Immunotherapy Advancements(Post)
Quick Facts About LemzoparlimabWhat is Lemzoparlimab?Lemzoparlimab is a monoclonal antibody that targets CD47, a protein known for its role in helping tumors evade the immune system. By
Passaging Hybridoma Cells: A Detailed Guide(Post)Cell Culture · ProtocolsPassaging Hybridoma Cells: A Detailed GuideHybridomas are productive but temperamental. They grow in suspension, are sensitive to shear and to overgrowth, and — the problem tha
Bersanlimab: Revolutionizing Cancer Research with Anti-CD47 Therapeutics(Post)What You Need to Know About BersanlimabWhat is Bersanlimab?Bersanlimab is a cutting-edge anti-CD47 monoclonal antibody designed to disrupt cancer cells' evasion of immune detection.What
No Ligand, No Kinase, No Problem(Post)HER2 has no ligand. HER3 has no kinase. Together they are the most potent signalling pair in human biology. That single sentence explains most of what is strange about this receptor family and all of
Valider en labo vos anticorps pour western blot : testez 2–3 dilutions(Post)Valider en labo vos anticorps pour western blot : testez 2–3 dilutions Pour un Western blot fiable, choisissez un anticorps validé sur des lysats biologiques pertinents, plutôt qu’un anticorps choisi
Tezepelumab: A Breakthrough in Severe Asthma Treatment and Research(Post)Quick Facts About TezepelumabWhat is Tezepelumab?Tezepelumab is a monoclonal antibody designed to inhibit thymic stromal lymphopoietin (TSLP), a key driver of airway inflammation in seve
Cabiralizumab: Unlocking the Potential of Anti-CSF1R Therapy(Post)What You Need to Know About CabiralizumabWhat is Cabiralizumab?Cabiralizumab is a monoclonal antibody targeting the colony-stimulating factor-1 receptor (CSF1R), developed for treating c
CD39: A Novel Target to Overcome Immunosuppression in Cancer(Post)Introduction to CD39 and Cancer Immunosuppression CD39 is an ectonucleotidase enzyme that plays a crucial role in generating adenosine, a powerful immunosuppressive molecule within the tu
Cyclins and Cyclin Dependent Kinase – Review(Post)Cell Cycle · KinasesCyclins and Cyclin-Dependent Kinases: Regulation, Substrates and Mitotic ControlCDKs are inactive on their own. They require a cyclin partner, and because cyclin levels rise and fa
Labetuzumab: Revolutionizing Cancer Research with Targeted Therapies(Post)Quick Facts About LabetuzumabWhat is Labetuzumab?Labetuzumab is a monoclonal antibody targeting CEACAM5, a protein overexpressed in various cancers, primarily colorectal carcinoma.How do
One Cytokine, Two Opposite Clinical Effects(Post)Low-dose IL-2 expands regulatory T cells. High-dose IL-2 expands the cells they exist to restrain. Same cytokine, same receptor family, opposite clinical intent — and the explanation is a receptor su
Th17 Cells and the IL-23 Axis(Page) Galegenimab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About GalegenimabWhat is Galegenimab?Galegenimab is an anti-CD47 monoclonal antibody designed to block the "don't eat me" signal, enhancing the immune system's ability to eli
Non-Alcoholic Fatty Liver Disease (NAFLD) - Biomarkers(Post)Key Points Non-alcoholic fatty liver disease (NAFLD) refe
Guselkumab: Advancing Psoriasis and Autoimmune Disease Research Through IL-23 Targeting(Post)Quick Facts About GuselkumabWhat is Guselkumab?Guselkumab is a biologic therapy that selectively targets the p19 subunit of interleukin-23 (IL-23), playing a critical role in inflammator
Tocilizumab: Advancing Therapeutics and Research with Biosimilars(Post)What You Need to Know About TocilizumabWhat is Tocilizumab?Tocilizumab is a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, widely used for managing autoimmune and in
Imalumab: Unveiling Its Mechanism, Clinical Potential, and Biosimilar Advancements(Post)What You Need to Know About ImalumabWhat is Imalumab?Imalumab is a monoclonal antibody targeting macrophage migration inhibitory factor (MIF), a key regulator of inflammation and immune
ELISA High Background Troubleshooting: FBS Matrix Interference(Post)Quick answer A researcher running a Rat Eotaxin/CCL11 (Eotaxin) sandwich ELISA saw sample readings sit above the top standard and wells turn colour the instant TMB was added — even aft
AACR 2025 - Scientific Progamme, Venue and Exhibits(Post)AACR 2025: Meet Assay Genie at the American Association for Cancer Research Assay Genie is delighted to be attending and exhibiting at AACR 2025 in Chicago, Illinois from the 25-30th of
Neutrophil Activation & NETosis(Page)